Kaleido Biosciences, Inc.
KLDO evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $4K
- Lead Asset:
- kb109 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for KLDO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$4K
Cash Runway
—
Lead Asset
kb109 (Preclinical)
Next Catalyst
—
Tracking 3 pipeline candidates for Kaleido Biosciences, Inc..
Run Kaleido Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kaleido Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$0
| Holder | Shares | Value |
|---|---|---|
| bay harbor wealth management, llc | 2,300 | $0 |
| hantz financial services, inc. | 350 | $0 |
| rmg wealth management llc | 70 | $0 |
Short Interest
as of May 21, 2026- % of float
- 14.2%
- Days to cover
- 29.3
- Shares short
- 2,339,422
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KLDO short interestFrequently asked questions
What is Kaleido Biosciences, Inc.'s lead drug candidate?
Kaleido Biosciences, Inc.'s most advanced tracked candidate is kb109 (Preclinical) for Mild to moderate COVID-19.
Who is the CEO of Kaleido Biosciences, Inc.?
Daniel L Menichella is the chief executive officer of Kaleido Biosciences, Inc. (KLDO).
Where is Kaleido Biosciences, Inc. headquartered?
Kaleido Biosciences, Inc. (KLDO) is headquartered in Lexington, MA, United States.
What therapeutic areas does Kaleido Biosciences, Inc. focus on?
Kaleido Biosciences, Inc. develops therapies across Immunology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.